Clinical Trials Logo

Secondary Hypogonadism clinical trials

View clinical trials related to Secondary Hypogonadism.

Filter by:

NCT ID: NCT01386606 Completed - Clinical trials for Secondary Hypogonadism

The Effect on Androxal Versus Androgel on Morning Testosterone in Men With Secondary Hypogonadism (Low Testosterone)

Start date: June 2011
Phase: Phase 2
Study type: Interventional

The study will determine the effects of three doses of Androxal(enclomiphene citrate)on morning testosterone versus AndroGel(approved topical treatment)in men with low testosterone (<350 ng/dL)after 6 weeks of continuous dosing.

NCT ID: NCT01270841 Completed - Clinical trials for Secondary Hypogonadism

Normalization of Morning Testosterone Levels in Men With Secondary Hypogonadism

Start date: January 2011
Phase: Phase 2
Study type: Interventional

The Purpose of the study is to determine the effects of Androxal on morning testosterone and reproductive status in men with secondary hypogonadism(confirmed morning Testosterone less than 250 ng/dL), compared to changes with placebo, or Testim (topical testosterone). The effects of Testim versus placebo on reproductive status will also be examined. Study subjects must not be currently using a topical testosterone.

NCT ID: NCT01191320 Completed - Clinical trials for Type 2 Diabetes Mellitus

Study to Evaluate the Efficacy of Androxal in Controlling Blood Glucose in Men With Type-2 Diabetes Mellitus

Start date: October 2010
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the effect the investigative drug has on glycemic control in men with type 2 diabetes mellitus (T2DM) and secondary hypogonadism

NCT ID: NCT01067365 Completed - Clinical trials for Secondary Hypogonadism

Study to Evaluate the Safety and Efficacy of Androxal Treatment in Men With Secondary Hypogonadism

ZA-003Ext
Start date: March 2006
Phase: Phase 3
Study type: Interventional

Subjects who completed ZA-003 were eligible to receive an additional year of treatment in this extension study.

NCT ID: NCT00962637 Completed - Clinical trials for Secondary Hypogonadism

Study to Evaluate the Safety and Efficacy of Androxalâ„¢ Treatment in Men With Secondary Hypogonadism

Start date: March 2006
Phase: Phase 3
Study type: Interventional

Approximately 4 to 5 million men in the U.S. are testosterone-deficient. Enclomiphene (trans-clomiphene) citrate (Androxal) was evaluated to determine if Androxal increased serum testosterone levels in men with secondary hypogonadism. Subjects were randomly assigned to 1 of 4 treatments groups. Appropriate amounts of medications were dispensed at each visit. Subjects took their medications orally or by rubbing it onto the skin (depending on the treatment assignment) once daily for up to 6 months. Treatment visits occurred at approximately 4-week intervals for Months 1, 2, and 3 and then at 6-week intervals for Months 4, 5, and 6.

NCT ID: NCT00911586 Completed - Clinical trials for Secondary Hypogonadism

Pharmacokinetic Study to Determine Time to Steady-state

Start date: July 2009
Phase: Phase 2
Study type: Interventional

The purpose of the study is to confirm how long (i.e., how many days) it takes to reach steady-state when testosterone undecanoate is administered twice daily.

NCT ID: NCT00706719 Completed - Clinical trials for Secondary Hypogonadism

To Evaluate Sperm Parameters in Men With Secondary Hypogonadism Previously Treated With Topical Testosterone

Start date: June 2008
Phase: Phase 2
Study type: Interventional

The study was designed to determine if Androxal® would affect sperm parameters (count, concentration, volume) in men with secondary hypogonadism who have been previously treated with topical testosterone.

NCT ID: NCT00467870 Completed - Hypogonadism Clinical Trials

Long-term Safety Study of Intramuscular Injections of 750 mg and 1000 mg Testosterone Undecanoate in Hypogonadal Men

TU
Start date: March 2006
Phase: Phase 3
Study type: Interventional

To evaluate the pharmacokinetics of TU 750 mg and TU 1000 mg via multiple measurements of serum total testosterone.